Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Deffered Revenue (2019 - 2025)

Silence Therapeutics' Non-Current Deffered Revenue history spans 7 years, with the latest figure at $55.5 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue rose 7.07% year-over-year to $55.5 million; the TTM value through Dec 2025 reached $55.5 million, up 7.07%, while the annual FY2025 figure was $55.5 million, 7.07% up from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $55.5 million at Silence Therapeutics, roughly flat from $55.3 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $97.7 million in Q4 2021 and bottomed at $51.8 million in Q4 2024.
  • The 5-year median for Non-Current Deffered Revenue is $55.9 million (2025), against an average of $64.7 million.
  • The largest annual shift saw Non-Current Deffered Revenue skyrocketed 44.17% in 2021 before it decreased 29.17% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $97.7 million in 2021, then dropped by 23.81% to $74.5 million in 2022, then fell by 1.81% to $73.1 million in 2023, then fell by 29.17% to $51.8 million in 2024, then rose by 7.07% to $55.5 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Non-Current Deffered Revenue are $55.5 million (Q4 2025), $55.3 million (Q3 2025), and $56.3 million (Q2 2025).